Alejandra Espinosa de los Monteros, director of vaccines at Asofarma, a Mexican subsidiary of Moderna Laboratories, estimated that in the first phase, the COVID vaccine will arrive in Mexico with a potential market of up to 500 thousand doses for the entire country.
In an interview with Óscar Mario Beteta of Los Tiempos de la Radio, the executive explained that this number of doses is only an estimate and takes into account the number of commercially distributed vaccines for respiratory diseases such as influenza, although the drug to prevent the coronavirus is still being investigated.
“We can talk about the potential of the market, and it refers to respiratory vaccines. Here in Mexico, there is a market of almost 500 thousand doses, and we see it with the flu, specifically in the private market.
“Maybe we think that it will be a simile in the market, but this is the first time that the vaccine comes to the private market so that people can buy it, but that is a potential that we can do. as a basis, “explained Espiona de los Monteros.
In that sense, he meant that next Friday, December 15, when the Moderna vaccine against COVID arrives in the country, but this until the week of December 18, when it will begin its distribution in hospitals and pharmacy chains around the Republic.
Cofepris has approved the sale of vaccines to Moderna and Pfizer
Last week, the Federal Commission for the Protection against Health Risks (Cofepris) approved health registration by Pfizer and Moderna.
According to an information sheet, the agency granted health registration to the Spikevax vaccine (monovalent XBB.1.5) from Moderna (requested through its legal representative in Mexico, Asofarma), and the Comirnaty vaccine (Ómicron).
In that sense, Alejandra Espinosa de los Monteros, director of vaccines at Asofarma, stated that a price has not been established for this drug, but he said that it is lower than the one sold in the United States, which exceeds 2 thousand. pesos, that is, 100 dollars.